Compare Globus Medical Inc. Class A Common Stock (GMED) vs Lemonade Inc (LMND) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.

While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.